Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses

Laith J. Abu-Raddad; Hiam Chemaitelly; Hadi M. Yassine; Fatiha M. Benslimane; Hebah A. Al Khatib; Patrick Tang; Joel A. Malek; Peter Coyle; Houssein H. Ayoub; Zaina Al Kanaani; Einas Al Kuwari; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F. Abdul Rahim; Gheyath K. Nasrallah; Mohamed Ghaith Al Kuwari; Hamad Eid Al Romaihi; Mohamed H. Al-Thani; Abdullatif Al Khal; Adeel A. Butt; Roberto Bertollini

Journal ArticleOPEN ACCESS

Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses

Journal of Travel Medicine (2021) 28(7)

DOI: 10.1093/jtm/taab083

58Citations

67Readers

Author supplied keywords

Cite

CITATION STYLE

APA

Abu-Raddad, L. J., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., … Bertollini, R. (2021). Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. Journal of Travel Medicine, 28(7). https://doi.org/10.1093/jtm/taab083

Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses

Author supplied keywords

Cite

Register to see more suggestions